Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100OYAV
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥643.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.7bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥4.6bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.33Tat 2022-06-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.34Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥852.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥486.2bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥178.2bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.322021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30¥126m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥567.7bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥563.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥4.2bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥534m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥272m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥63.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥63.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥113m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥444m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥650.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥643.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥3.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Short term loans payableCurrentQuarterInstant30000000JPY
Income taxes payablePrior1YearInstant10922000000JPY
Income taxes payableCurrentQuarterInstant5819000000JPY
Provision for bonusesPrior1YearInstant6835000000JPY
Provision for bonusesCurrentQuarterInstant8169000000JPY
Provision for directors bonusesPrior1YearInstant407000000JPY
Provision for directors bonusesCurrentQuarterInstant153000000JPY
Provision for share based remuneration clPrior1YearInstant44000000JPY
Provision for share based remuneration clCurrentQuarterInstant－JPY
Provision for share based remuneration for directors and other officers clPrior1YearInstant59000000JPY
Provision for share based remuneration for directors and other officers clCurrentQuarterInstant－JPY
Other clPrior1YearInstant29245000000JPY
Other clCurrentQuarterInstant29350000000JPY
Current liabilitiesPrior1YearInstant802813000000JPY
Current liabilitiesCurrentQuarterInstant823529000000JPY
Provision for share based remuneration nclPrior1YearInstant－JPY
Provision for share based remuneration nclCurrentQuarterInstant19000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant－JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant24000000JPY
Provision for loss on anti monopoly act provisionsPrior1YearInstant3994000000JPY
Provision for loss on anti monopoly act provisionsCurrentQuarterInstant3994000000JPY
Net defined benefit liabilityPrior1YearInstant8075000000JPY
Net defined benefit liabilityCurrentQuarterInstant8058000000JPY
Other nclPrior1YearInstant17273000000JPY
Other nclCurrentQuarterInstant16910000000JPY
Noncurrent liabilitiesPrior1YearInstant29343000000JPY
Noncurrent liabilitiesCurrentQuarterInstant29008000000JPY
LiabilitiesPrior1YearInstant832156000000JPY
LiabilitiesCurrentQuarterInstant852538000000JPY
Capital stockPrior1YearInstant18454000000JPY
Capital stockCurrentQuarterInstant18454000000JPY
Capital surplusPrior1YearInstant101660000000JPY
Capital surplusCurrentQuarterInstant101660000000JPY
Retained earningsPrior1YearInstant352015000000JPY
Retained earningsCurrentQuarterInstant348671000000JPY
Treasury stockPrior1YearInstant-44625000000JPY
Treasury stockCurrentQuarterInstant-44625000000JPY
Shareholders equityPrior1YearInstant427504000000JPY
Shareholders equityCurrentQuarterInstant424160000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant44760000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant51784000000JPY
Deferred gains or losses on hedgesPrior1YearInstant0JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-0JPY
Revaluation reserve for landPrior1YearInstant-3360000000JPY
Revaluation reserve for landCurrentQuarterInstant-3360000000JPY
Foreign currency translation adjustmentPrior1YearInstant200000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant278000000JPY
Remeasurements of defined benefit plansPrior1YearInstant2487000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant2347000000JPY
Valuation and translation adjustmentsPrior1YearInstant44088000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass